Free tool
FAERS Monitor: Coly-Mycin S
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050356 or its brand name (Coly-Mycin S, Colistin Sulfate, Hydrocortisone Acetate, Neomycin Sulfate, Thonzonium Bromide). Reports on generic versions are filed under their own applications.
Reports
2
Serious
2
100% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- asthenia1
- central nervous system lymphoma1
- colitis1
- dehydration1
- diarrhoea1
- dizziness postural1
- dysstasia1
- endophthalmitis1
- fatigue1
- general physical health deterioration1
- malignant neoplasm progression1
- nausea1
- ocular discomfort1
- oedema peripheral1
- pollakiuria1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| central nervous system lymphoma | 1 | 7639.4 | 1908.6 | 1,908 |
| endophthalmitis | 1 | 1753.3 | 438.4 | 437 |
| dizziness postural | 1 | 1084.7 | 271.2 | 270 |
| ocular discomfort | 1 | 936.7 | 234.2 | 233 |
| dysstasia | 1 | 360.2 | 90.1 | 89 |
| colitis | 1 | 277.4 | 69.4 | 68 |
| pollakiuria | 1 | 252.2 | 63.1 | 62 |
| malignant neoplasm progression | 1 | 102.7 | 25.7 | 25 |
| general physical health deterioration | 1 | 90.9 | 22.7 | 22 |
| oedema peripheral | 1 | 86.3 | 21.6 | 21 |
| dehydration | 1 | 78.8 | 19.7 | 19 |
| asthenia | 1 | 28.0 | 7.0 | 6 |
| diarrhoea | 1 | 16.3 | 4.1 | 3 |
| fatigue | 1 | 13.5 | 3.4 | 3 |
| nausea | 1 | 13.3 | 3.3 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.